Lite Strategy, Inc.
$1.19
▼
-0.88%
2026-04-21 07:54:01
www.litestrategy.com
NCM: LITS
Explore Lite Strategy, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$42.54 M
Current Price
$1.19
52W High / Low
$9 / $0.95
Stock P/E
—
Book Value
$2.23
Dividend Yield
0%
ROCE
-103.09%
ROE
-76.38%
Face Value
—
EPS
$-1.82
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
0.1
Debt / Equity
—
Current Ratio
10.04
Quick Ratio
13.5
Forward P/E
—
Price / Sales
—
Enterprise Value
$33.42 M
EV / EBITDA
-2.07
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Abeona Therapeutics Inc. | $5.48 | 4.39 | $312.63 M | — | -47.08% | 70.05% | $7.54 / $4 | $2.89 |
| 2. | Calidi Biotherapeutics, Inc. | $0.25 | — | $3 M | — | -410.2% | -7.01% | $19.2 / $0.21 | $0.51 |
| 3. | Minerva Neurosciences, Inc. | $6.89 | — | $289.51 M | — | -15.79% | 352.58% | $12.46 / $1.3 | $-3.25 |
| 4. | Ovid Therapeutics Inc. | $2.89 | — | $381.12 M | — | -29.75% | -17.51% | $3.1 / $0.27 | $1 |
| 5. | MacroGenics, Inc. | $3.48 | — | $228.17 M | — | -34.08% | -86.94% | $3.88 / $1.11 | $0.88 |
| 6. | Royalty Pharma plc | $49.52 | 27.78 | $28.52 B | 1.91% | 8.21% | 13.2% | $50.08 / $31.58 | $15.11 |
| 7. | Coeptis Therapeutics Holdings, Inc. | $15.54 | — | $91.17 M | — | -90.67% | -1.37% | $21.41 / $6.26 | $2.36 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.35 M | -3.11 M | -2.88 M | -2.77 M | -3.45 M | — |
| Net Profit | -30.8 M | -3.64 M | -2.69 M | -2.57 M | -2.68 M | — |
| EPS in Rs | -0.85 | -0.1 | -0.07 | -0.07 | -0.07 | -1.2 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 65.3 M | 48.82 M | 40.7 M |
| Operating Profit | -17.45 M | 25.44 M | -36.76 M | -75.48 M |
| Net Profit | -15.95 M | 17.78 M | -31.84 M | -54.45 M |
| EPS in Rs | -0.44 | 0.49 | -0.88 | -1.5 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 18.29 M | 41.38 M | 120.81 M | 177.84 M |
| Total Liabilities | 1.35 M | 8.36 M | 96.19 M | 125.43 M |
| Equity | 16.93 M | 33.02 M | 24.62 M | 52.41 M |
| Current Assets | 18.29 M | 40.77 M | 107.53 M | 167.13 M |
| Current Liabilities | 1.35 M | 8.36 M | 20.34 M | 24.44 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -20.84 M | -50.47 M | -52.48 M | -48.75 M |
| Investing CF | 35.15 M | 49.14 M | 53.69 M | 6.89 M |
| Financing CF | 0 M | -11.87 M | -0.04 M | 49.05 M |
| Free CF | -20.84 M | -50.48 M | -52.52 M | -49.23 M |
| Capex | — | -0.01 M | -0.04 M | -0.48 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 33.76% | 19.95% | — | — |
| Earnings Growth % | 155.84% | 41.53% | — | — |
| Profit Margin % | 27.23% | -65.22% | -133.8% | — |
| Operating Margin % | 38.96% | -75.31% | -185.48% | — |
| Gross Margin % | — | — | 100% | — |
| EBITDA Margin % | 39.55% | -74.52% | -184.68% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2023-11-16 | $1.75 |
Stock Splits
| Date | Split |
|---|---|
| 2023-04-17 | 1:0.05 |